The generation of the SARS-CoV-2 Spike RBD recombinant monoclonal antibody involves a multistep process. Initially, the SARS-CoV-2 Spike RBD monoclonal antibody is harvested, and its gene sequence is analyzed. Next, a vector that carries the SARS-CoV-2 Spike RBD monoclonal antibody gene is created and transfected into a host cell line for culturing. During the SARS-CoV-2 Spike RBD monoclonal antibody production, a recombinant human SARS-CoV-2 Spike glycoprotein (S) (319-541aa) (CSB-YP3324GMY1 and CSB-MP3324GMY1b1) is used as an immunogen. The SARS-CoV-2 Spike RBD recombinant monoclonal antibody is then purified via affinity chromatography and assessed for specificity using ELISA. It is labeled with an HRP tag.

The spike protein of SARS-CoV-2, including the receptor-binding domain (RBD) on the spike protein, plays a crucial role in the virus's entry into human cells. The RBD specifically binds to the human cell surface receptor ACE2, allowing the virus to enter and infect the cell. The RBD is a highly specific and critical component of the virus's ability to infect human cells. Mutations in the RBD have been shown to impact the virus's ability to infect cells and the severity of the disease it causes. It is a significant target for vaccine development and therapeutics aimed at preventing or treating COVID-19.

The process for generating the MS4A1 recombinant monoclonal antibody involves obtaining the MS4A1 antibody genes, introducing these genes into suitable host cells, and utilizing a cellular expression and translation system to synthesize the MS4A1 antibodies. This method offers significant advantages, including enhanced purity and stability of the resulting MS4A1 recombinant monoclonal antibodies, as well as improved antibody affinity and specificity. The MS4A1 recombinant monoclonal antibody is subjected to purification using affinity chromatography and undergoes thorough testing through ELISA, IHC, and IF assays. It is noteworthy that this antibody exclusively targets the human MS4A1 protein.

The main role of the MS4A1 protein (CD20) is to serve as a cell surface marker on B cells, where it contributes to B cell activation and is a key target for therapeutic interventions in B cell-related diseases and autoimmune conditions.